Keerthi Sanapala
Keerthi Sanapala has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ashesh Das
Independent researcher, Department of Gastroenterology, Mayo Clinic, Rochester, USA
2 shared publications - Harshawardhan Dhanraj Ramteke
Anhui Medical University
2 shared publications - Rakhshanda Khan
Ayaan Institute Of Medical Sciences, Hyderabad, India
2 shared publications - Akash Rawat
Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India
1 shared publication - Ambala Madhulikha
Kamineni Academy of Medical Sciences and Research
1 shared publication - Bharadwaj Jilakaraju
Archbold medical center, USA
1 shared publication
Latest Publications
- Open Access
Peroral Endoscopic Myotomy Versus Laparoscopic Heller Myotomy for Achalasia: A Meta-Analysis of Randomized Controlled Trials
Introduction: Achalasia is a rare primary esophageal motility disorder characterized by impaired lower esophageal sphincter relaxation and dysphagia. Laparoscopic Heller myotomy (LHM) has long been the standard treatment, while peroral endoscopic myotomy (POEM) has emerged as a minimally invasive alternative. Comparative evidence from randomized controlled trials (RCTs) remains limited, and outcomes such as gastroesophageal reflux disease (GERD) and clinical remission require clarification. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science to September 2025 for RCTs comparing POEM and LHM in adult patients with achalasia. Data on demographics, previous treatment, dysphagia improvement, GERD incidence, clinical remission, and mortality were extracted. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model in Stata 18. Results: Seven RCTs involving 900 patients (465 POEM; 465 LHM) were included. Dysphagia improvement was similar between groups (log OR 0.14; 95% CI −0.32 to 0.59; p = 0.55). GERD incidence was higher after POEM but not statistically significant (log OR 0.59; 95% CI −0.08 to 1.25; p = 0.08). Clinical remission showed a non-significant trend favoring POEM (log OR 0.39; 95% CI −0.06 to 0.84; p = 0.09). Reduction in pH levels significantly favored LHM (log OR 0.75; 95% CI 0.18 to 1.33; p = 0.01). No mortality was reported. Conclusion: POEM and LHM provide comparable dysphagia relief and clinical remission in achalasia. However, POEM is associated with higher GERD risk, particularly on pH monitoring. Treatment choice should balance efficacy against reflux risk, with careful long-term follow-up.
Open AccessPeroral Endoscopic Myotomy Versus Laparoscopic Heller Myotomy for Achalasia: A Meta-Analysis of Randomized Controlled Trials
Introduction: Achalasia is a rare primary esophageal motility disorder characterized by impaired lower esophageal sphincter relaxation and dysphagia. Laparoscopic Heller myotomy (LHM) has long been the standard treatment, while peroral endoscopic myotomy (POEM) has emerged as a minimally invasive alternative. Comparative evidence from randomized controlled trials (RCTs) remains limited, and outcomes such as gastroesophageal reflux disease (GERD) and clinical remission require clarification. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science to September 2025 for RCTs comparing POEM and LHM in adult patients with achalasia. Data on demographics, previous treatment, dysphagia improvement, GERD incidence, clinical remission, and mortality were extracted. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model in Stata 18. Results: Seven RCTs involving 900 patients (465 POEM; 465 LHM) were included. Dysphagia improvement was similar between groups (log OR 0.14; 95% CI −0.32 to 0.59; p = 0.55). GERD incidence was higher after POEM but not statistically significant (log OR 0.59; 95% CI −0.08 to 1.25; p = 0.08). Clinical remission showed a non-significant trend favoring POEM (log OR 0.39; 95% CI −0.06 to 0.84; p = 0.09). Reduction in pH levels significantly favored LHM (log OR 0.75; 95% CI 0.18 to 1.33; p = 0.01). No mortality was reported. Conclusion: POEM and LHM provide comparable dysphagia relief and clinical remission in achalasia. However, POEM is associated with higher GERD risk, particularly on pH monitoring. Treatment choice should balance efficacy against reflux risk, with careful long-term follow-up.
- Open Access
Comparative Efficacy and Safety of Medical Treatments for Cushing’s Disease: A Systematic Review and Network Meta-Analysis
Introduction: Cushing’s disease (CD) is a rare endocrine disorder characterized by excessive cortisol production due to a pituitary adenoma secreting ACTH, leading to a range of systemic effects including obesity, hypertension, and hyperglycemia. The condition is often underdiagnosed, with an incidence of 2-3 cases per million people annually. While surgery remains the first-line treatment, adjunctive medical therapies are essential for non-surgical candidates or those with recurrent disease. This systematic review and network meta-analysis (NMA) evaluate the comparative efficacy and safety of medical treatments for Cushing’s disease. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and observational studies published between 2010 and 2023. Studies were included if they assessed the efficacy and/or safety of medical treatments for Cushing’s disease. Data extraction was performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs and ROBS 2.0 for observational studies. Network meta-analysis was performed using a random-effects model to compare treatments across different outcomes. Results: A total of 29 studies involving 1,736 patients were included in the analysis. The patient cohort comprised 600 males (34.5%) and 1,132 females (65.5%), with an average age of 41.09 years. Among the treatments, 960 patients (55.3%) received Pasireotide, 143 (8.2%) Osilodrostat, 126 (7.3%) Mifepristone, and 176 (10.1%) Levoketoconazole. In terms of 24-hour urinary free cortisol (UFC) reduction, Levoketoconazole showed a mean difference of -329 (95% CI: -2.33e+03, 1.70e+03), Mifepristone -381 (95% CI: -3.27e+03, 1.74e+03), Osilodrostat -214 (95% CI: -1.60e+03, 1.25e+03), and Pasireotide -331 (95% CI: -1.75e+03, 1.09e+03). Despite all treatments reducing UFC levels, the broad confidence intervals suggest substantial uncertainty in the efficacy estimates. Regarding the change in cortisol levels, Mifepristone showed a mean difference of 290 (95% CI: -285, 888), Osilodrostat 15.6 (95% CI: -806, 835), and Pasireotide -6.17 (95% CI: -821, 815), indicating considerable variability in treatment effects. The analysis of ACTH levels revealed similar trends, with Levoketoconazole and Mifepristone showing more pronounced reductions compared to Osilodrostat. In terms of overall survival, Levoketoconazole demonstrated a survival rate of 0.82 (95% CI: 0.72–0.91), while Mifepristone had a pooled survival rate of 0.94 (95% CI: 0.86–1.02). The analysis of disease-free survival indicated an overall pooled survival rate of 0.80 (95% CI: 0.70–0.90). Quality of life (QOL) improvements were variable, with Osilodrostat showing a mean difference of -11.72 (95% CI: -18.32, -5.12). There were no significant differences in the risk of gastrointestinal, cardiovascular, or neurological adverse events between treatments. Conclusion: This systematic review and network meta-analysis provide valuable insights into the comparative efficacy and safety of medical treatments for Cushing’s disease. While Pasireotide and Levoketoconazole consistently reduce UFC levels, Mifepristone and Osilodrostat also show potential, albeit with greater variability in clinical outcomes. The high heterogeneity observed across studies suggests the need for further research to refine treatment strategies and optimize patient management. Personalized treatment approaches, incorporating both efficacy and safety considerations, will be crucial for improving outcomes and minimizing the burden of this disease.
Open AccessComparative Efficacy and Safety of Medical Treatments for Cushing’s Disease: A Systematic Review and Network Meta-Analysis
Introduction: Cushing’s disease (CD) is a rare endocrine disorder characterized by excessive cortisol production due to a pituitary adenoma secreting ACTH, leading to a range of systemic effects including obesity, hypertension, and hyperglycemia. The condition is often underdiagnosed, with an incidence of 2-3 cases per million people annually. While surgery remains the first-line treatment, adjunctive medical therapies are essential for non-surgical candidates or those with recurrent disease. This systematic review and network meta-analysis (NMA) evaluate the comparative efficacy and safety of medical treatments for Cushing’s disease. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and observational studies published between 2010 and 2023. Studies were included if they assessed the efficacy and/or safety of medical treatments for Cushing’s disease. Data extraction was performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs and ROBS 2.0 for observational studies. Network meta-analysis was performed using a random-effects model to compare treatments across different outcomes. Results: A total of 29 studies involving 1,736 patients were included in the analysis. The patient cohort comprised 600 males (34.5%) and 1,132 females (65.5%), with an average age of 41.09 years. Among the treatments, 960 patients (55.3%) received Pasireotide, 143 (8.2%) Osilodrostat, 126 (7.3%) Mifepristone, and 176 (10.1%) Levoketoconazole. In terms of 24-hour urinary free cortisol (UFC) reduction, Levoketoconazole showed a mean difference of -329 (95% CI: -2.33e+03, 1.70e+03), Mifepristone -381 (95% CI: -3.27e+03, 1.74e+03), Osilodrostat -214 (95% CI: -1.60e+03, 1.25e+03), and Pasireotide -331 (95% CI: -1.75e+03, 1.09e+03). Despite all treatments reducing UFC levels, the broad confidence intervals suggest substantial uncertainty in the efficacy estimates. Regarding the change in cortisol levels, Mifepristone showed a mean difference of 290 (95% CI: -285, 888), Osilodrostat 15.6 (95% CI: -806, 835), and Pasireotide -6.17 (95% CI: -821, 815), indicating considerable variability in treatment effects. The analysis of ACTH levels revealed similar trends, with Levoketoconazole and Mifepristone showing more pronounced reductions compared to Osilodrostat. In terms of overall survival, Levoketoconazole demonstrated a survival rate of 0.82 (95% CI: 0.72–0.91), while Mifepristone had a pooled survival rate of 0.94 (95% CI: 0.86–1.02). The analysis of disease-free survival indicated an overall pooled survival rate of 0.80 (95% CI: 0.70–0.90). Quality of life (QOL) improvements were variable, with Osilodrostat showing a mean difference of -11.72 (95% CI: -18.32, -5.12). There were no significant differences in the risk of gastrointestinal, cardiovascular, or neurological adverse events between treatments. Conclusion: This systematic review and network meta-analysis provide valuable insights into the comparative efficacy and safety of medical treatments for Cushing’s disease. While Pasireotide and Levoketoconazole consistently reduce UFC levels, Mifepristone and Osilodrostat also show potential, albeit with greater variability in clinical outcomes. The high heterogeneity observed across studies suggests the need for further research to refine treatment strategies and optimize patient management. Personalized treatment approaches, incorporating both efficacy and safety considerations, will be crucial for improving outcomes and minimizing the burden of this disease.